Abstract
Supporting evidence from previous clinical studies provides a substantiative rationale for Osimertinib (O; third-generation EGFR-TKI) and Teliso-V (T; c-Met TKI inhibitor) combination therapy for the treatment (Tx) of patients (pts) with metastatic/advanced EGFR-mut c-Met overexpressed (OE) NSCLC following progression on prior O. Here we report updated safety and efficacy results of a phase 1b study (NCT02099058) for T+O combination (Arm E).
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call